Novavax COVID-19 vaccine booster appears effective after primary vaccination

By Amerigo Allegretto, The Science Advisory Board contributing writer

August 6, 2021 -- Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew a 4.6-fold increase in functional antibody titers.

The booster dose had a sixfold increase in cross-reactive functional antibodies to the coronavirus delta variant compared to the primary vaccination series, the company said. Analysis of sera from the primary vaccination series also showed cross-reactive functional antibodies to alpha, beta, and delta variants, all of which increased six- to tenfold with the booster dose.

The results come from an ongoing phase II study in the U.S. and Australia in which participants in one cohort received a 5-μg booster dose 189 days after the initial two-dose vaccine regimen to examine the functional immune response. The company also noted that the booster dose was "generally well tolerated."

Novavax touts COVID-19 vaccine results
Novavax is highlighting study results that demonstrate the efficacy of its COVID-19 vaccine, NVX-CoV2373, as well as a new COVID-19 vaccine it is developing...
Novavax posts positive preclinical results for flu/COVID-19 vaccine
Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine.
Novavax COVID vaccine effective vs. B.1.351 variant, inks deal with Gavi
Novavax announced results of a phase IIB trial of its COVID-19 candidate vaccine (NVX-CoV2373) published May 5 in the New England Journal of Medicine...
Novavax expands COVID-19 vaccine trial to include adolescents
Novavax has started a pediatric expansion of its phase III clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against...
Novavax COVID-19 vaccine to be included in combo vaccine study
Novavax announced it will participate in a newly expanded phase II trial to study NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate. The...

Copyright © 2021 scienceboard.net


Conferences
BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter